ADC Therapeutics SA — Investor Relations & Filings
Filings indexed
396
across all filing types
Latest filing
2026-05-04
Regulatory Filings
Country
US
United States of America
Listing
US
ADCT
ADC Therapeutics SA is a commercial-stage biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for cancer therapy. The company focuses on creating highly potent and targeted ADCs to treat hematologic malignancies and solid tumors, addressing significant unmet medical needs. Its primary product, ZYNLONTA® (loncastuximab tesirine-lpyl), is an FDA-approved anti-CD19 ADC for adults with relapsed or refractory large B-cell lymphoma. The company's research and development pipeline includes a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker, aimed at treating solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - ADC Therapeutics SA (0001771910) (Filer) | 2026-05-04 | English | |
| DEF 14A - ADC Therapeutics SA (0001771910) (Filer) | 2026-04-20 | English | |
| EFFECT - ADC Therapeutics SA (0001771910) (Filer) | 2026-03-17 | English | |
| 8-K - ADC THERAPEUTICS SA (0001771910) (Filer) | 2026-02-23 | English | |
| 4 - ADC THERAPEUTICS SA (0001771910) (Filer) | 2026-02-18 | English | |
| 4 - ADC THERAPEUTICS SA (0001771910) (Filer) | 2026-02-18 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 40883041 | 8-K - ADC Therapeutics SA (0001771910) (Filer) | 2026-05-04 | English | ||
| 34691265 | DEF 14A - ADC Therapeutics SA (0001771910) (Filer) | 2026-04-20 | English | ||
| 32962993 | EFFECT - ADC Therapeutics SA (0001771910) (Filer) | 2026-03-17 | English | ||
| 32898023 | 8-K - ADC THERAPEUTICS SA (0001771910) (Filer) | 2026-02-23 | English | ||
| 32898018 | 4 - ADC THERAPEUTICS SA (0001771910) (Filer) | 2026-02-18 | English | ||
| 32898019 | 4 - ADC THERAPEUTICS SA (0001771910) (Filer) | 2026-02-18 | English | ||
| 32898021 | 4 - ADC THERAPEUTICS SA (0001771910) (Filer) | 2026-02-18 | English | ||
| 32898020 | 4 - ADC THERAPEUTICS SA (0001771910) (Filer) | 2026-02-18 | English | ||
| 32898022 | 4 - ADC THERAPEUTICS SA (0001771910) (Filer) | 2026-02-18 | English | ||
| 31657188 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31657048 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31657045 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31657109 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 13170966 | FORM 8-K | 2026-01-12 | English | ||
| 13170967 | 8-K | 2026-01-08 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
ADC Therapeutics SA via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32916/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32916 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32916 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32916 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32916}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ADC Therapeutics SA (id: 32916)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.